601607 上海医药
2026/06 - 中期
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额4,449,5096,154,2015,827,2585,231,5204,743,361
投资活动产生之现金流量净额393,596(3,982,230)415,980(2,491,873)(12,473,124)
筹资活动产生之现金流量净额(948,390)(5,651,768)(1,863,930)231,85112,138,594
汇率变动对现金及现金等价物的影响(8,971)(3,116)2,157(5,580)(12,440)
现金及现金等价物净增加/(减少)3,885,744(3,482,912)4,381,4642,965,9184,396,391
期初现金及现金等价物余额28,398,36131,881,27327,499,80924,533,89120,137,500
期末现金及现金等价物余额32,284,10528,398,36131,881,27327,499,80924,533,891